The introduction of Bruton tyrosine kinase (BTK) inhibitors has significantly improved outcomes for patients with relapsed/refractory mantle cell lymphoma (MCL), and these therapies are now widely used.
Newer generations of BTK inhibitors have shown progression-free survival of nearly 3 years as well as improved safety profiles. Unfortunately, progression on BTK inhibitor therapy occurs in most patients.
Chimeric antigen receptor (CAR) T-cell therapy with brexucabtagene autoleucel has emerged as a third-line option, providing a median duration of response of 28 months. Because of the risk for toxicity, however, not all patients are candidates for CAR T-cell therapy.
In this ReCAP, Dr Jeremy Abramson from Massachusetts General Cancer Center in Boston reports on therapeutic options available for patients with relapsed/refractory MCL, including the newly US FDA–approved noncovalent BTK inhibitor pirtobrutinib.
Dr Abramson also discusses emerging treatment options, including combination targeted therapies, bispecific antibodies, and antibody-drug conjugates such as zilovertamab vedotin, which has shown encouraging responses in phase 1 trials.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment Options for Relapsed/Refractory Mantle Cell Lymphoma - Medscape - Feb 17, 2023.
Comments